mFOLFOXIRI with or without bevacizumab for conversion therapy of <i>RAS/BRAF/PIK3CA</i> mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial.

Ann Transl Med · 2022 · PMC8908129 · PMID 35280386

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Conclusions We observed that the combination of mFOLFOXIRI and bevacizumab increased the rate of clinical NED and showed a trend toward improved survival compared with mFOLFOXIRI alone.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.